MUTYH and neoplasm: Specifically, non-BRCA1/2 variants were identified in an additional 13% of tumour samples in our study (APC, BRIP1, CDKN2A, MSH3, MUTYH, PALB2, PTEN, RAD51C, and RAD51D).